Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
Clinical Program to Expand Globally Following Positive Phase I Clinical Results SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm (ASX:NOX) has...






